
Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma.


Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.

Br J Haematol 2010;149(4):529-36

Kornacker M, Kornacker B, Schmitt C, Leo E, Ho AD, Hensel M.

Commercial LightCycler-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma.


Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.


Oberneder R, Weckermann D, Ebner B, Quadt, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E

A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients

Eur J Cancer 2006; 42(15):2530-8

One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?

Leukemia Res 2006; 30(12):1563-8

Schmitt C, Balogh B, Grundt A, Buchholtz C, Leo A, Benner A, Hensel M; Meuer S, Ho AD, Leo E

The Bcl-2/IgH rearrangement in a population of 204 healthy individuals: Occurrence, age and gender distribution, break points and detection method validity


Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma.


T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.


Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.

Eur J Hematol 2004; 73:251-7

Leo E, Krämer A, Krasnqi F, Hochhaus A, Hehlmann R, Ho AD

Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy.

Kornacker M, Kraemer A, Leo E, Ho AD

**Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.**

*Ann Hematol* 2002; Feb;81(2):103-5.

Leo E, Deveraux Q, Buchholtz C, Welsh K, Matsuzawa S, Stennicke H, Salvesen GS, Reed JC

**TRAF1 is cleaved by caspases during TNF- and FAS-mediated apoptosis.**


Ni CZ, Welsh K, Leo E, Chiou CK, Wu H, Reed JC, Ely KE

**Crystal structure of the signaling protein TRAF3 bound to a fragment of CD40.**


Zapata JM, Matsuzawa S, Godzik A, Leo E, Wasserman SA, Reed JC

**The drosophila tumor necrosis factor receptor-associated factor-1 (D-TRAF1) interacts with pelle and regulates NF-kB activity.**


Leo E, Zapata JM, Reed JC

**CD40-Mediated activation of Ig-C1-and Ig-C-gemline promoters involves multiple TRAF-family proteins.**


**TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction.**

*J Biol Chem* 1999; 274(42):30202-8
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC

**Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases.**

*EMBO J* 1999; 18(19):5242-51

Leo E, Welsh K, Matsuzawa S, Zapata JM, Kitada S, Mitchell RS, Ely KR, Reed JC

**Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and JunN-terminal kinase activation.**


Leo E, Schlegel PG, Lindemann A

**Chemotherapeutic induction of long-term remission in metastatic medulloblastoma.**

*J Neurooncology* 1997; 32(2):149-54

Leo E, Kropff M, Lindemann A, Steinfurth G, Esselborn H, Rossner R, Adler CP, Bocking A

**DNA aneuploidy, increased proliferation and nuclear area of plasma cells in monoclonal gammopathy of undetermined significance and multiple myeloma.**

*Anal Quant Cyt Histol* 1995; 17(2):113-20

Kropff M, Leo E, Steinfurth G, Adler CP, Bocking A.

**DNA-cytometry and clinical staging systems in prognosis of multiple myeloma.**

*Anticancer Res* 1994; 14: 2183-8
ABSTRACTS/TALKS


Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

American Society of Hematology 2011; Annual Meeting; #673


Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia.

American Society of Hematology 2011; Annual Meeting; #48


A Phase II Open-Label, AC220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-ITD Positive Acute Myeloid Leukemia : Updated Interim Results

American Society of Hematology 2011; Annual Meeting; #614


A phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations: Interim Results

European Hematology Association 2011, Annual Meeting, London. #1014

Leo E

Are There Ways to Truly Accelerate Early Drug Development?

“Latest Advances on Anticancer Drugs in Clinical Development”;

5th European Spring Oncology Conference; Marbella, Málaga, Spain. June 26, 2008


Stuehmer T, Arts J, King P, Borawski J, Page M, Leo E, Bargou RC

Preclinical evaluation of the novel HDAC-inhibitor JNJ-26481585 in multiple myeloma reveals strong anti-tumor activity

American Association for Cancer Research 2008; Annual Meeting. #738


JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies.

American Association for Cancer Research 2008; Annual Meeting. #1592

Stuehmer T, Arts J, King P, Page M, Bommert K, Leo E, Bargou RC

A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo.

J Clin Oncol 2008; Suppl 26; May 20; #14694


Preclinical anti-tumor studies with JNJ-26854165 – A novel class of Hdm2 antagonist
IN CLINICAL DEVELOPMENT

NCI-EORTC-AACR Conference on Targeted Therapies 2007, Washington D.C.
Bommert K, Knop S, Arts J, King P, Page M, Leo E, Bargou R

Novel 2nd generation histone deacetylase inhibitor (JNJ-26481585) exhibits potent antitumor activity against chronic lymphocytic leukemia cells in vitro and ex vivo.

American Society of Hematology 2007; Annual Meeting


The anti-CD19 bispecific T-cell engager (BiTE) MT103 (MEDI-538), induces dose-dependent objective complete and partial responses in relapsed non-Hodgkin’s lymphoma (NHL): update from the ongoing phase I study MT103-104.

American Society of Hematology 2007; Annual Meeting


JNJ-26481585: a novel “second-generation” oral pan-Histone Deacetylase (HDAC) inhibitor showing broad-spectrum preclinical antitumoral activity against solid tumors and hematological malignancies

Discovery on Target conference 2007; Boston


The bi-specific T-cell enhancer (BiTE) MT103 (MEDI-538) induces clinical responses in heavily pre-treated NHL patients: Update from the ongoing phase I study MT103-104.

American Society of Hematology 2006; Annual Meeting, # 2725


T cell responses during long-term continuous infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in patients with relapsed B-NHL.

American Society of Hematology 2006; Annual Meeting, # 693

*European Hematology Association 2006; Annual Meeting, # 0189 & #0503*


**How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).**

*Blood (ASH Annual Meeting Abstracts), 2004; 104: 4584.*

Heidenreich A, Ohlmann C, Leo E, Bäuerle PA, Da Silva A, Roessler S, Barth P, Moll R

**Epithelial cell adhesion molecule (Ep-CAM) – a potential therapeutic target in prostate cancer (PCA)**

*Deutsche Gesellschaft für Urologie; Jahrestagung*

Balogh B, Leo E, Grundt A, Buchholtz C, Ho AD, Schmitt C

**Monitoring Minimal Residual Disease (MRD): Comparing two frequently used techniques regarding feasibility, sensitivity/specificity and economics for detection of the bcl-2/igH rearrangement**

*ESEC-ESMO Meeting 2005; Budapest*


**Wieviel Rituximab ist erforderlich zur Erzielung hoher molekularer und klinischer Remissionsraten: Eine multizentrische, randomisierte Studie zum Vergleich von 1, 3 oder 6 Rituximab-Infusionen in Kombination mit 6 Zyklen CHOP bei unbehandelten Patienten mit fortgeschrittenem follikulares Non-Hodgkin Lymphom.**

*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2004; Jahreskongress*
Balogh B, Buchholtz C, Richter P, Ho AD, Leo E
Frequency of t(14;18) translocation in healthy individuals
Proceedings of the American Society of Clinical Oncology 2003; 20, 292a

Leo E, Scheuer L, Kraemer A, Kerowgan M, Leo A, Ho AD
Unexpected hematotoxicity associated with a combination of rituximab, fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.
American Society of Hematology 2001; Annual Meeting, # 4745

Kraemer A, Zoz M, Krasniqi F, Goerner M, Leo E, Ho AD
Treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma with a combination of a taxane, cyclophosphamide and rituximab.
American Society of Hematology 2001; Annual Meeting, # 569

Leo E, Bertz H, Koehler G, Colgan JP, Kurtin , Finke J
Treatment of agressive, recurrent, subcutaneous panniculitis-like T-cell non-Hodgkin's lymphoma (SPTCL) with high-dose chemotherapy followed by allogeneic peripheral blood stem cell transplantation.
American Society of Hematology 2001, Annual Meeting, # 5287

Probst S, Leo E, Kraemer A, Egerer G, Haas R, Ho AD
Autologous transplantation as primary treatment strategy vs. at relapse for follicular lymphoma upon long term follow-up.
American Society of Hematology 2001, Annual Meeting, # 5376

High-dose therapy with autologous stem cell transplantation for patients with follicular low grade non-Hodgkin's lymphoma - an analysis of late effects of transplantation
Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2001; Jahreskongress
Probst S, Leo E, Kraemer A, Egerer G, Haas R, Ho AD
**Primary treatment strategy versus at relapse for follicular lymphoma upon long term follow-up.**
*American Society of Hematology 2000; Annual Meeting*

Zoz M, Krämer A, Krasniqi F, Görner M, Leo E, Ho AD
**Taxane, cyclophosphamide plus rituximab in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. (Onkologie 2001)**
*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2001; Jahreskongress*

**Long-term outcome and adverse events in patients with low-grade follicular lymphoma after autologous transplantation.**
*Proceedings of the American Society of Clinical Oncology 2001; 20 292a*

Leo E, Bertz H, Köhler G, Finke J
**Successful treatment of aggressive, recurrent subcutaneous panniculitis-like T-cell non-Hodgkin's lymphoma (SPTLC) with high-dose chemotherapy followed by allogeneic peripheral blood stem cell transplantation.**
*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2001; Jahreskongress+*

Leo E, Ciamango O, Krasniqi F, Krämer A, Ho AD
**Gangrene of the toes during hydroxy-urea therapy in chronic myelogenous leukemia - a case report.**
*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2000; Jahreskongress*

Leo E, Loeber T, Deveraux Q, Welsh K, Stennicke H, Salvesen GS, Reed JC
**A distinct region of the Human Inhibitor of Apoptosis (IAP) protein cIAP1 interacts with caspases 3, -7 and -9.**
*American Society of Hematology 2000; Annual Meeting*
Leo E, Deveraux Q, Matsuzawa S, Welsh K, Reed JC
TRAF1 is cleaved by caspases during TNF- and Fas-mediated apoptosis
American Association for Cancer Research 2000; Annual Meeting

Leo E, Deveraux Q, Matsuzawa S, Welsh K, Reed JC
TRAF1 is cleaved by caspases during TNF- and Fas-mediated apoptosis
American Association for Cancer Research 2000; Annual Meeting

Leo E, Zapata JM
Reed JC CD40-Mediated activation of Ig-Cgamma1-and Ig-Cepsilon-germline promoters involves multiple TRAF-family proteins.
American Society of Hematology 1999; Annual Meeting

Leo E, Welsh K, Matsuzawa S and Reed, JC
TRAF2 and TRAF3 are non-essential for CD40 activation of NF-kB.
American Association for Cancer Research 1999; Annual Meeting

Leo E, Kropff M, Lindemann A, Adler C, Oster W, Boecking A
DNA-Aneuploidy, increased proliferation and nuclear area of plasma cells as early markers of prospective malignancy in Monoclonal Gammopathy of Undetermined Significance.
American Association for Cancer Research 1992; Annual Meeting

Kropff M, Leo E, Steinfurth G, Adler CP, Böcking A
DNA-zytometrischer Nachweis von Aneuploidie, erhöhter Proliferation und Kernfläche als frühe Marker prospektiver Malignität bei monoklonaler Gammopathie unklarer Signifikanz (MGUS)
Verh Dtsch Ges Path 1991; 75, 480